Flerie ABFRA:1NP1 -0.29%28 Quick Ratio is 100.43 as of Mar. 2026, which is 926% above its 10-year median of 9.79. GuruFocus rates FRA:1NP1 with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, Flerie AB ranks better than 99.57% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Flerie AB's quick ratio for the quarter that ended in Mar. 2026 was 100.43.
Flerie AB has a quick ratio of 100.43. It generally indicates good short-term financial strength.
The historical rank and industry rank for Flerie AB's Quick Ratio or its related term are showing as below:
FRA:1NP1'
s Quick Ratio Range Over the Past 10 Years
Min: 0.43 Med: 9.79 Max: 120.16
Current: 100.41
During the past 12 years, Flerie AB's highest Quick Ratio was 120.16. The lowest was 0.43. And the median was 9.79.
FRA:1NP1's Quick Ratio is ranked better than 99.57% of 1411
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:1NP1: 100.41
Flerie AB (FRA:1NP1) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Flerie AB Quick Ratio Related Terms
Flerie AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for Flerie AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1NP1 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Flerie AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flerie AB Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Flerie AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Flerie AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Flerie AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flerie AB (FRA:1NP1) has a Quick Ratio of 100.43 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Flerie AB and its competitors. This is 926% above median its historical median of 9.79. Over the past decade, Flerie AB's Quick Ratio has ranged from 0.43 to 120.16. According to the industry distribution chart, Flerie AB ranks #6 out of 1411 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is Flerie AB's Quick Ratio too high?
Flerie AB's current Quick Ratio of 100.43 is 926% above median its 10-year median of 9.79. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 120.16. The Biotechnology industry median Quick Ratio is 3.60. Flerie AB's value of 100.43 is 2689.7% above this industry median. Based on the distribution chart, Flerie AB ranks #6 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Flerie AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Flerie AB ranks #6 out of 1411 companies for Quick Ratio. This places Flerie AB in the top 0% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Flerie AB's value of 100.43 is 2689.7% above this benchmark. Historically, Flerie AB's own Quick Ratio has ranged from 0.43 to 120.16 over the past decade. While the company's 10-year median is 9.79 vs. the industry median of 3.60, Flerie AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Flerie AB's current Quick Ratio of 100.43 is 2689.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Flerie AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Flerie AB's current Quick Ratio is 100.43, which is 926% above median its own 10-year median of 9.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (FRA:1NP1) has a current Quick Ratio of 100.43. The current Quick Ratio is 100.43, which is 926% above median its 10-year median of 9.79 and 2689.7% above the Biotechnology industry median of 3.60. Flerie AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Flerie AB (FRA:1NP1), the current Quick Ratio is 100.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
28GF Score
Get the complete analysis for FRA:1NP1
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1NP1 has been successfully added to your 
